Inventiva SA
IVA4.440USD
+0.060+1.37%
收盤 12/24, 13:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Inventiva SA 公司
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Inventiva SA簡介
公司代碼IVA
公司名稱Inventiva SA
上市日期Feb 15, 2017
CEOObenshain (Andrew)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址50 rue de Dijon
城市DAIX
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編21121
電話33380447500
網址https://inventivapharma.com/
公司代碼IVA
上市日期Feb 15, 2017
CEOObenshain (Andrew)
Inventiva SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Andre Turenne
Andre Turenne
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月21日 週五
更新時間: 11月21日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Samsara BioCapital, LLC
3.73%
Yiheng Capital Management, L.P.
1.90%
New Enterprise Associates (NEA)
1.05%
BVF Partners L.P.
0.49%
Millennium Management LLC
0.08%
其他
92.74%
持股股東
持股股東
佔比
Samsara BioCapital, LLC
3.73%
Yiheng Capital Management, L.P.
1.90%
New Enterprise Associates (NEA)
1.05%
BVF Partners L.P.
0.49%
Millennium Management LLC
0.08%
其他
92.74%
股東類型
持股股東
佔比
Venture Capital
4.78%
Investment Advisor
2.01%
Hedge Fund
0.57%
Research Firm
0.02%
Investment Advisor/Hedge Fund
0.02%
其他
92.59%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Jun 30, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
Jun 30, 2025
Commonwealth Financial Network
54.32K
0.06%
-169.00
-0.31%
Jun 30, 2025
Morgan Stanley & Co. International Plc
2.10K
0%
+2.10K
--
Jun 30, 2025
Wealth Enhancement Advisory Services, LLC
16.56K
0.02%
+5.84K
+54.53%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Inventiva SA的前五大股東是誰？
Inventiva SA的前五大股東如下：
Yiheng Capital Management, L.P.持有股份：2.64M佔總股份比例：2.76%。
New Enterprise Associates (NEA)持有股份：1.46M佔總股份比例：1.53%。
BVF Partners L.P.持有股份：686.04K佔總股份比例：0.72%。
Commonwealth Financial Network持有股份：54.32K佔總股份比例：0.06%。
Morgan Stanley & Co. International Plc持有股份：2.10K佔總股份比例：0.00%。
Yiheng Capital Management, L.P.持有股份：2.64M佔總股份比例：2.76%。
New Enterprise Associates (NEA)持有股份：1.46M佔總股份比例：1.53%。
BVF Partners L.P.持有股份：686.04K佔總股份比例：0.72%。
Commonwealth Financial Network持有股份：54.32K佔總股份比例：0.06%。
Morgan Stanley & Co. International Plc持有股份：2.10K佔總股份比例：0.00%。
Inventiva SA的前三大股東類型是什麼？
Inventiva SA 的前三大股東類型分別是：
Samsara BioCapital, LLC
Yiheng Capital Management, L.P.
New Enterprise Associates (NEA)
Samsara BioCapital, LLC
Yiheng Capital Management, L.P.
New Enterprise Associates (NEA)
有多少機構持有Inventiva SA(IVA)的股份？
截至2025Q3，共有21家機構持有Inventiva SA的股份，合計持有的股份價值約為4.95M，占公司總股份的5.18% 。與2025Q2相比，機構持股有所增加，增幅為0.09%。
哪個業務部門對Inventiva SA的收入貢獻最大？
在--，--業務部門對Inventiva SA的收入貢獻最大，創收--，占總收入的--% 。
